Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025

The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green CNS(Vafidemstat) Received...
November 04, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces Positive Clinical Data of Iadademstat at ASH-2025

Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual MeetingPreliminary data from the ongoing Phase Ib trial combining iadademstat with azacitidine and...
November 03, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease

Recently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to raise fetal hemoglobin (HbF) in adult patients with SCDIadademstat has demonstrated a favorable...
October 30, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Participate in Upcoming Events in November

MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in...
October 28, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs

To enhance and accelerate regulatory dialogue with the FDA To provide strategic guidance across clinical development programsTo bring deep expertise in CNS and immuno-oncology MADRID and CAMBRIDGE,...
October 17, 2025 12:08 ET | Source: Oryzon Genomics, S.A.

ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder

Provides clarity on the aspects to incorporateCompany to address them and resubmit revised protocol MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
October 01, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors

MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics,...
September 25, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Participate in Upcoming Events in September and October

MADRID and CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics,...
September 22, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Sponsor First Phelan-McDermid Syndrome (PMS) Burden of Illness Study

Study led by CureShankAims to characterize the direct and indirect burden of PMS to patients, caregivers, and US healthcare system MADRID and CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) --...
September 16, 2025 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant

MADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics,...